Across TCGA pan-cancer cohorts, RAD54B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAD54B data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RAD54B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD54B expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, LIHC, and COAD are the cancer types where RAD54B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.825	.003	36	view →
LIHC	OS	Median	All	0.166	0.693	<.001	30	view →
COAD	OS	Median	III,IV	0.056	0.783	<.001	12	view →
SKCM	DFS	Median	All	0.904	0.600	.026	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RAD54B tumor-vs-normal RNA expression · all RAD54B data types